Russell Investments Group, Ltd. Avadel Pharmaceuticals PLC Transaction History

Russell Investments Group, Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$12.55 - $17.22 $1.44 Million - $1.98 Million	115,041 New	115,041 $1.94 Million
Q3 2020 Nov 09, 2020	SELL	$5.02 - $8.98 $311,169 - $556,634	-61,986 Closed	0 $0
Q2 2020 Aug 05, 2020	BUY	$7.25 - $11.75 $449,398 - $728,335	61,986 New	61,986 $499,000
Q2 2018 Aug 08, 2018	SELL	$5.89 - $7.78 $29,756 - $39,304	-5,052 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$6.76 - $11.7 $129,940 - $224,897	-19,222 Reduced 79.19%	5,052 $37,000
Q4 2017 Feb 06, 2018	SELL	$8.03 - $11.25 $3.41 Million - $4.78 Million	-424,512 Reduced 94.59%	24,274 $199,000
Q3 2017 Nov 07, 2017	BUY	$8.35 - $10.5 $3.75 Million - $4.71 Million	448,786	448,786 $4.71 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.